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A B ST R AC T 
 
 
Lungs have long been considered sterile, but recent research 
has shown that a large number of microbiological organisms 
exist in the lungs of healthy subjects (including bacteria, 
fungi, and viruses), collectively known as the microbiome. It 
undergoes changes in patients with respiratory pathology. 
Studies in idiopathic pulmonary fibrosis show that a large 
number of bacteria or the abundant presence of potentially 
pathogenic bacteria can cause disease progression and 
exacerbation, and can implicitly increase mortality. There 
seems to be a quantitative balance, a well-established 
proportion between the components of this microbiome, 
which is disturbed during a disease and can reach a "state of 
pulmonary dysbiosis". Evidence suggests that the 
microbiome may be used as a prognostic biomarker and may 
also explain the pathogenesis of interstitial fibrosis. 
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The microbiome consists of microorganisms (and their 
products) that are physiologically found in the human body 
[1]. The human microbiota is made up of trillions of 
symbiotic microbial cells, mainly bacteria in the intestine; 
in addition to this, viruses (including bacteriophages), 
fungi, and archaea (archaebacteria, part of the oral, 
intestinal and vaginal microbiome) are also identified [1,2]. 
Projects on the microbiome, from all over the world, have 
been launched in order to understand the roles that these 
germs play in the appearance and evolution of different 
pathologies, as well as their impact on human health. The 
human body and microorganisms have coexisted for 
millions of years, so the immune system of the human body 
and the microbiome are closely linked [1,3]. Apparently, 
each compartment of the human body has a unique 
microbiome made up of specific microorganisms, and 
consequently the respiratory tree has its own microbiome 
[1]. 
The purpose of the current review is to analyze 
idiopathic pulmonary fibrosis, a disease with fatal impact, 
from the point of view of the pulmonary microbiome and 
the benefits it may bring to our knowledge in the evolution 
of the disease.  
Discussions 
The experimental part 
Studies that aimed to determine the composition of the 
microbiome in the healthy man, in the patient with 
diagnosed idiopathic pulmonary fibrosis, and the 
modification of the microbiome in the context of the 
evolution of the disease and exacerbations (where the 
patients' condition allowed) were analyzed. 
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Most of the studies that investigated the human 
microbiome insisted on the intestinal one, considering the 
wide range of bacteria found at this level. Also, in the 
oropharynx, skin, vagina, and nasal cavity, the microbiome 
was easier studied in comparison with the lung, due not 
only to greater accessibility, but also to the large number 
of present microorganisms [4].  
The microbiome controversy is about the physiological 
colonization of the respiratory tree. Lungs have long been 
considered sterile because standard microbiological culture 
techniques consistently give negative results [5], only 1% 
of bacteria can be grown in normal laboratories [6]. In the 
last decade, however, the use of molecular techniques has 
shown that this theory is incorrect and that a large number 
of microbiological organisms (including bacteria, fungi, 
and viruses), collectively known as the microbiome, 
coexist in the lungs not only of healthy subjects, but also in 
patients with respiratory diseases[5]. 
The challenges for describing the respiratory 
microbiome are increasing and take into account the 
difficulty obtaining samples from the lower respiratory 
tract as well as their contamination in the upper respiratory 
tract [1]. 
The respiratory mucosa is host to numerous micro-
organisms. The lung microbiome evaluation studies were 
based on the analysis of bronchoalveolar lavage obtained 
by bronchoscopy [1]. This technique is widely used to 
study and highlight the pathogenetic mechanisms and 
inflammatory response through the influx of pro-
inflammatory cells [7]. Although sputum examination is a 
less invasive method compared to bronchoscopy, it 
presents an increased risk of contamination when passing 
through the oropharyngeal cavity [1]. 
The most representative bacteria in the respiratory tract 
have so far proved to be: Bacteroidetes (including 
Prevotella sp.), Firmicutes (including Streptococcus sp. 
and Veillonella sp.) and, in lower quantities, Proteobacteria 
and Actinobacteria [8–10]. It is worth mentioning that 
despite the difference in pH, temperature, and oxygen 
concentration, the microbiome in healthy subjects is 
relatively constant. 
The composition of the microbiome is influenced by 
mucociliary clearance and host defense mechanisms, local 
growth factors contributing very little to the composition 
of the microbiome in healthy lungs [9]. Smoking can 
directly affect the composition of the microbiome, which 
can lead to changes in the structure of microorganisms 
[11].  
Various types of bacteria promote inflammation in the 
respiratory tract. Although they are less common 
(Haemophilus influenzae, Moraxella catarrhalis, 
Streptococcus pneumoniae, Haemophilus parainfluenzae, 
Staphylococcus aureus, and Pseudomonas aeruginosa), 
their persistence in the respiratory tract favors chronic 
respiratory diseases and chronic inflammation [12–14]. 
These microorganisms become particular in the case of 
certain pathologies, and the overlap and agglomeration of 
bacterial species decrease the physiological species 
richness of the pulmonary microbiota and are associated 
with the evolution of some diseases [15]. 
All of these bacterial species carry a unique imprint, a 
distinct complement of genomic DNA. Since it is 
impossible to completely sequence each genome in each 
cell, microbial ecology has defined a series of molecular 
markers that express a DNA sequence which identifies that 
particular genome [16]. 
Several markers have been evaluated over time, 
including ribosomal protein subunits, growth factors, and 
RNA polymerase subunits. The most present and 
historically significant is the small or 16S ribosomal RNA 
subunit gene, commonly referred to as 16s rRNA [16,17]. 
This subunit is present in the genome of all bacteria, 
making it easy to identify bacteriological sequences and is 
the target site for amplification or sequencing [18]. The 
rRNA-16s sequencing identifies bacterial DNA in 97% of 
the cases that have benefited from bronchial lavage, 
compared to the conventional culture technique, which 
detects bacteria in 39.1% of the lavage sample [8]. 
Pulmonary microbiome and idiopathic pulmonary 
fibrosis 
Interstitial lung disease (ILD) is a heterogeneous group 
of conditions with similar clinical, imaging, and 
histopathological features. While some are associated with 
immune impairment, others are allergic or even idiopathic. 
The pathogenesis of these diseases is not fully elucidated; 
the exaggeration of the host's immune response, which acts 
as a continuous stimulant to the alveolar epithelium, may 
be a triggering mechanism of the disease [19]. The 
pathogenesis of pulmonary fibrosis is complex and may be 
specific for different agents, with the destruction of 
pulmonary architecture [20] 
Few studies have been carried out on the microbiome 
in interstitial lung disease. However, more recent studies 
suggest the importance and connection of the lung 
microbiome with respiratory pathologies, including 
interstitial pulmonary fibrosis (IPF) [1]. Recent studies 
have described the microbiome from stable idiopathic 
pulmonary fibrosis and correlated the microbial 
composition and bacterial load with the evolution of 
pulmonary fibrosis [21]. The lung microbiome was 
evaluated in patients with IPF in the (COMET) -IPF 
(Correlating Outcomes with biochemical Markers to 
Estimate Time-progression) study, and the most prevalent 
identified bacteria were Prevotella, Veillonella and 
Cronobacter species (spp.) [22].  
As research into the composition of the microbiome in 
IPF is in its early stages, correlations with intensively 
studied pathologies (such as COPD) and with healthy 
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subjects were analyzed through PCR studies from 
bronchoalveolar lavage. Patients with IPF had a 
significantly higher bacterial load compared to the COPD 
group and the healthy group. The most abundant species 
present in these groups were Streptococcus, Prevotella, and 
Veillonella spp. and patients with IPF showed lower 
bacterial diversity compared to the control group, 
harboring potentially pathogenic bacteria such as 
Haemophilus, Neisseria and Streptococcus spp. [23]. 
Among patients with IPF, high bacterial load was 
associated with a significant decrease in survival time 
compared to those with lower bacterial load, an effect that 
is independent of age and tobacco use [23-25]. 
 Interestingly, patients with IPF who have the MUC5B 
minor allele genotype, previously at increased risk of 
developing IPF and playing an important role in 
mucociliary clearance [26,27], had significantly lower 
bacterial burden compared with patients with IPFs that do 
not have this genotype [23]. 
Different studies have evaluated gene expression in 
blood samples and polymorphisms of MUC5B genes in 
patients with IPF, compared to healthy control groups. 
Overexpression of a gene in the IPF group was associated 
with death and disease progression, with a high level of 
neutrophils in both peripheral blood and bronchoalveolar 
lavage, a high bacterial load in bronchoalveolar lavage, and 
a relatively low amount of Neisseria sp [28]. 
After adjusting the parameters (age, gender, smoking 
status, presence of gastroesophageal reflux, baseline lung 
function, and 6-minute walk test), the presence of 
Streptococcus or Staphylococcus over a certain limit was 
associated with a significant clinical reduction in survival. 
This finding shows that potentially pathogenic 
microorganisms (Streptococcus and Staphylococcus sp.) 
are associated with an increased risk of disease progression 
in humans, coinciding with exacerbation of pulmonary 
fibrosis in 2 specimens of mice infected with Streptococcus 
pneumonia [22]. 
We must not forget that there are a number of 
limitations in the evaluation of the lung microbiome in the 
context of an exacerbation. The worsening of the 
respiratory condition, with significant desaturations can 
prevent the obtaining of bronchoalveolar lavage. Also, the 
administration of the antibiotic before the harvest 
influences the obtained material.  
An acute exacerbation of idiopathic pulmonary fibrosis 
(AE-IPF)) has been defined as an acute clinical worsening 
of dyspnea, which develops in less than 1 month without 
an alternative etiology.  
While AE-IPF is increasingly recognized and perceived 
as a severe event with high mortality, there is only a limited 
amount of clinical data on exacerbation of other interstitial 
lung pathologies [29]. Precisely from this more accurate 
identification of IPF, the pulmonary microbiome was 
further studied in the context of exacerbation of IPF, which 
does not yet have a definite conclusion. Some studies 
incriminate Staphylococcus and Streptococcus in 
aggravating the underlying disease [19]. 
Molecular techniques have identified several common 
pathogenic viruses that appear in exacerbation, including 
respiratory syncytial virus and cytomegalvirus [30]. 
Described as molecular techniques applied to sputum 
cultures of patients with acute exacerbation, 89% of gram-
negative bacteria with pathogenic potential were found: 
Klebsiella pneumonia (26%), Mycobacterium tuberculosis 
(21%), and Acinetobacter baumannii (10%) were the 
dominant sputum samples [31]. 
PF progression includes exacerbations like other 
respiratory pathologies. Acute exacerbations have been 
associated with poor prognosis. Patients who died by 
exacerbation had a higher percentage of neutrophils in the 
bronchoalveolar fluid and a lower number of lymphocytes 
in the same sample, compared to those who survived an 
exacerbation [32]. The correlation of the neutrophils with 
the change in the composition of the lung microbiome 
could be a key for future studies. 
Also, the role of acute phase PCR protein has been 
studied, which has been shown to be an independent 
predictor of survival, and a viral or bacterial infection and/ 
or inflammation may be one of the pathogenic mechanisms 
of exacerbation [32,33]. Patients with IPF who experienced 
an exacerbation were found to have four times greater 
bacterial load compared to patients with stable IPF from 
the control group, who met the same criteria for age, 
gender, smoking status, and lung volume.  
 Exacerbated patients had a higher colony of 
Proteobacteria sp and potentially pathogens such as 
Campylobacter and Stenotrophomonas spp. [34]; 
Campylobacter is known to be a pathogen that originates 
from the gastrointestinal tract. This finding supports the 
idea that gastroesophageal reflux would contribute to 
exacerbations in IPF [35,36]. 
 Evaluation of the microbiome from the sputum of 
patients with idiopathic pulmonary fibrosis showed an 
increase in bacterial load with Campylobacter sp. and 
Stenotrophomonas sp., together with a significant decrease 
of Veillonella sp. [34]  
The contribution of viral infections, including viral 
hepatitis C, transfused viruses, and herpes virus has been 
intensively studied, but with conflicting results regarding 
their importance in the pathogenesis of the disease [37]. 
Herpetic viruses (including Epstein-Barr virus, 
cytomegalovirus, herpes simplex virus, and human herpes 
virus-7 and -8) have been identified in a large proportion 
in the lung tissue of IPF patients, compared to the control 
group [38] and similar viruses have developed fibrosis in 
experimental animals [37]. These data are influenced by 
the immunosuppressive treatment given to patients with 
The lung microbiome in patients with idiopathic pulmonary fibrosis 
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IPF, but may suggest that viruses are co-factors in the 
progression of pulmonary fibrosis [21]. 
Lowering of respiratory infections is a benefit on 
overall mortality in patients with IPF who have received 
antibiotic therapy with cotrimoxazole [39]. The standard 
treatment of idiopathic pulmonary fibrosis with the main 
antifibrotic agents (Pirfenidone and Nintedanib) has as a 
secondary effect the modification of the intestinal motility 
[39], through the transit modifications that it favors 
(diarrhea and constipation). 
Modification of the intestinal microbiome favors 
respiratory infections [40], with all the implications 
described above, practically proving that in patients with 
IPF, they are very difficult to control. In this context, an 
ideal therapeutic agent should combine the antimicrobial, 
antiviral, and antifibrotic effects [41,42], although it 
remains to be discussed whether alternative therapies 
would have antiviral, antimicrobial, anti-inflammatory and 
antifibrotic effects [43,44] 
Herbal remedies such as Black Elder (Sambucus nigra 
L.) have been identified so far  which associates antiviral 
(herpes simplex virus type 1, influenza virus) and 
antimicrobial (Streptococcus pneumoniae, Haemophilus 
influenza, Streptococcus pyogenes, group C and G 
Streptococci, Branhamella caterrhalis, and Haemophilus 
influenza) [45] effects, with demonstrated myocardial 
antifibrotic effects [46]  and renal tissue [47]. 
Analyzing the previously described aspects, we find 
that the progression of idiopathic pulmonary fibrosis is 
correlated with the modification of the respiratory 
microbiome. There is also some evidence to suggest that 
viral infection may be responsible for a proportion of acute 
exacerbations of IPF. The role of the bacteria in the 
pathogenesis of IPF is less clear. Studies of other 
respiratory diseases suggest that changes in the lung 
microbiome are associated with the disease and that these 
changes influence the behavior of the disease [37]. 
Conclusions 
Interest in the lung microbiome has grown steadily over 
the past decade, proving through various studies that 
respiratory microbiota microorganisms play an important 
role in maintaining the health-disease balance. 
Respiratory tract dysbiosis causes an irregular immune 
response, which in turn can promote host susceptibility to 
infections, with the deepening microbial imbalance.  
In the evolution of chronic lung disease, the 
microbiome could help select appropriate, targeted, and 
more personalized antibiotics during the disease, especially 
in exacerbations of idiopathic pulmonary fibrosis.  
In this context, more advanced metagenomic analyses 
are needed to elucidate the functional role of individual 
genes and bacterial communities in the progression of 
idiopathic pulmonary fibrosis.  
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